Diagnostic scoring for familial hypercholesterolaemia in practice

Current Opinion in Lipidology

Volumn 27, Issue 4, 2016, Pages 367-374

  Haralambos, Kate ^a   Ashfield Watt, Pauline ^a   McDowell, Ian F W ^a,b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b CARDIFF AND VALE UNIVERSITY HEALTH BOARD   (United Kingdom)

Author keywords

diagnosis; familial hypercholesterolaemia; phenotype; scoring systems

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

CLINICAL PRACTICE; CORNEA CURVATURE; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILY HISTORY; GENETIC HETEROGENEITY; GENETIC SCREENING; GENETIC VARIABILITY; HUMAN; ISCHEMIC HEART DISEASE; MEDICAL SOCIETY; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; UNITED KINGDOM; UNITED STATES; AGE; COMPLICATION; DIAGNOSTIC PROCEDURE; METABOLISM; SEX DIFFERENCE; STANDARDS;

AGE FACTORS; BIOMARKERS; DIAGNOSTIC TECHNIQUES AND PROCEDURES; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; SEX FACTORS;

EID: 84978736631     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000325     Document Type: Review

References (29)

1. Teramoto T, Sasaki J, Ueshima H, et al., Japan Atherosclerosis Society (JAS) Committee for Epidemiology and Clinical Management of Atherosclerosis. Diagnostic criteria for dyslipidemia. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb 2007; 14:155-158.
2. Harada-Shiba M1, Arai H, Okamura T, et al. Multicenter study to determine the diagnosis criteria of heterozygous familial hypercholesterolemia in Japan. J Atheroscler Thromb 2012; 19:1019-1026.
3. Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ 1991; 303:893-896.
4. National Collaborating Centre for Primary Care (UK) (2008). CG71 Identification and Management of Familial Hypercholesterolaemia. London: Royal College of General Practitioners (UK) Available from: https://www. nice. org. uk/guidance/cg71.
5. Williams RR, Hunt SC, Schumacher C, et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol 1993; 72:171-176.
6. Brahm AJ, Hegele RA. Combined hyperlipidemia: familial but not (usually) monogenic. Curr Opin Lipidol 2016; 27:131-140.
7. Haralambos K, Whatley SD, Edwards R, et al. Clinical experience of scoring criteria for familial hypercholesterolaemia (FH) genetic testing in Wales. Atherosclerosis 2015; 240:190-196.
8. World Health Organization. Familial hypercholesterolemia: report of a second WHO Consultation. Geneva, Switzerland: World Health Organization; 1999.
9. Defesche JC. Familial hypercholesterolaemia. In: Betteridge DJ, editor. Lipids and vascular disease. London, UK: Martin Dunitz; 2000. pp. 65-76.
10. Nordestgaard BG, Chapman JM, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 2013; 34:3478-3490.
11. Ashfield-Watt PAL, Haralambos K, Sharif B, et al. Web based tools to assess eligibility for genetic testing for familial hypercholesterolaemia (FH). Atherosclerosis 2016; 245:e245.
12. Civeira F, Ros E, Estibaliz J, et al. Comparison of genetic versus clinical diagnosis in familial hypercholesterolemia. Am J Cardiol 2008; 102:1187-1193.
13. Weng SF, Kai J, Neil HA, et al. Improving identification of FH in primary care: Derivation and validation of the familial hypercholesterolaemia case ascertainment tool (FAMCAT). Atherosclerosis 2015; 238:336-343
14. Genest J, Hegele RA, Bergeron J, et al. Canadian Cardiovascular Society position statement on familial hypercholesterolemia. Can J Cardiol 2014; 30:e1471-e1481.
15. Besseling J, Reitsma JB, Gaudet D, et al. Selection of individuals for genetic testing for familial hypercholesterolaemia: development and external validation of a prediction model for the presence of a mutation causing familial hypercholesterolaemia. Eur Heart J 2016; doi: 10. 1093/eurheartj/ehw135. [Epub ahead of print]
16. Damgaard D, Larsen ML, Nissen PH, et al. The relationship of molecular genetic to clinical diagnosis of familial hypercholesterolemia in a Danish population. Atherosclerosis 2005; 180:155-160.
17. Clarke RE, Padayachee. Preston R, et al. Effectiveness of alternative strategies to define index case phenotypes to aid genetic diagnosis of familial hypercholesterolaemia. Heart 2013; 99:175e180.
18. Benn M, Watts GF, Tybjærg-Hansen A, Nordestgaard BG. Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217. Eur Heart J 2016; 37:1384-1394.
19. Leren TP, Berge KP. Identification of mutations in the apolipoprotein B-100 gene and in the PCSK9 gene as the cause of hypocholesterolemia. Clin Chim Acta 2008; 397:92-95.
20. Humphries SE, Cranston T, Allen M, et al. Mutational analysis in UK patients with a clinical diagnosis of familial hypercholesterolaemia: relationship with plasma lipid traits, heart disease risk and utility in relative tracing. J Mol Med 2006; 84:203-214.
21. Fouchier SW, Dallinga-Thie GM, Meijers JC, et al. Mutations in STAP1 are associated with autosomal dominant hypercholesterolemia. Circ Res 2014; 115:552-555.
22. Lange LA, Hu Y, Zhang H, Xue C, et al., NHLBI Grand Opportunity Exome Sequencing Project. Whole-exome sequencing identifies rare and low-frequency coding variants associated with LDL cholesterol. Am J Hum Genet 2014; 94:233-245.
23. Stitziel NO, Fouchier SW, Sjouke B, et al. Exome sequencing and directed clinical phenotyping diagnose cholesterol ester storage disease presenting as autosomal recessive hypercholesterolemia. Arterioscler Thromb Vasc Biol 2013; 33:2909-2914.
24. Futema M, Plagnol V, Whittall RA, et al. Use of targeted exome sequencing as a diagnostic tool for familial hypercholesterolaemia. J Med Genet 2012; 49:644-649.
25. Talmud P, Shah S, Whittall R, et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: A case-control study. Lancet 2013; 381:1293-1301.
26. Futema M, Shah S, Cooper J, Li K, et al. Refinement of variant selection for the LDL cholesterol genetic risk score in the diagnosis of the polygenic form of clinical familial hypercholesterolemia and replication in samples from 6 countries. Clin Chem 2015; 61:231-238.
27. Civeira F, Jarauta E, Cenarro A, et al. Frequency of low-density lipoprotein receptor gene mutations in patients with a clinical diagnosis of familial combined hyperlipidemia in a clinical setting. J Am Coll Cardiol 2008; 52:1546-1553.
28. Koivisto PV, Koivisto UM, Miettinen TA, Kontula K. Diagnosis of heterozygous familial hypercholesterolemia DNA analysis complements clinical examination and analysis of serum lipid levels. Arterioscler Thromb Vasc Biol 1992; 12:584e592.
29. Leren TP, Manshaus T, Skovholt U, et al. Application of molecular genetics for diagnosing familial hypercholesterolemia in Norway: results from a familybased screening program. Semin Vasc Med 2004; 4:75-85